Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Dow
Healthtrust
Accenture
Moodys
UBS
US Department of Justice
Julphar
Cerilliant

Generated: August 17, 2018

DrugPatentWatch Database Preview

Alvogen Company Profile

« Back to Dashboard

Summary for Alvogen
International Patents:1
US Patents:1
Tradenames:38
Ingredients:35
NDAs:45
Patent Litigation for Alvogen: See patent lawsuits for Alvogen

Drugs and US Patents for Alvogen

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alvogen FLUOXETINE HYDROCHLORIDE fluoxetine hydrochloride TABLET;ORAL 202133-001 Oct 6, 2011 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Alvogen Inc PRIMAQUINE PHOSPHATE primaquine phosphate TABLET;ORAL 203924-001 Feb 3, 2014 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Alvogen Pine Brook OSELTAMIVIR PHOSPHATE oseltamivir phosphate FOR SUSPENSION;ORAL 208823-001 Oct 31, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Alvogen Malta ZESTRIL lisinopril TABLET;ORAL 019777-006 Jan 20, 1999 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Alvogen Pine Brook ESTRADIOL estradiol CREAM;VAGINAL 209767-001 Mar 5, 2018 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Alvogen FORFIVO XL bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 022497-001 Nov 10, 2011 RX Yes Yes 7,674,479 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Alvogen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alvogen Malta TENORMIN atenolol TABLET;ORAL 018240-002 Approved Prior to Jan 1, 1982 3,836,671 ➤ Try a Free Trial
Alvogen ADALAT CC nifedipine TABLET, EXTENDED RELEASE;ORAL 020198-003 Apr 21, 1993 5,264,446 ➤ Try a Free Trial
Alvogen Malta ZESTORETIC hydrochlorothiazide; lisinopril TABLET;ORAL 019888-002 Jul 20, 1989 4,374,829*PED ➤ Try a Free Trial
Alvogen Malta ZESTRIL lisinopril TABLET;ORAL 019777-005 Apr 29, 1993 4,374,829*PED ➤ Try a Free Trial
Alvogen Malta TENORMIN atenolol TABLET;ORAL 018240-001 Approved Prior to Jan 1, 1982 3,836,671 ➤ Try a Free Trial
Alvogen Malta TENORETIC 50 atenolol; chlorthalidone TABLET;ORAL 018760-002 Jun 8, 1984 3,934,032 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ALVOGEN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 450 mg ➤ Subscribe 2013-02-28

Non-Orange Book US Patents for Alvogen

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,703,191 Controlled-release pharmaceutical tablets ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Alvogen Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90064-1 Sweden ➤ Try a Free Trial PRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
666 Luxembourg ➤ Try a Free Trial PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119
C0041 Belgium ➤ Try a Free Trial PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606
C0030 France ➤ Try a Free Trial PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
/2000 Austria ➤ Try a Free Trial PRODUCT NAME: BUPROPION HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-23680 20000616; FIRST REGISTRATION: NL 24160 19991201
C/GB01/047 United Kingdom ➤ Try a Free Trial PRODUCT NAME: NATEGLINIDE; REGISTERED: CH 55401 01 20000928; CH 55401 02 20000928; UK EU/1/01/174/001 20010403; UK EU/1/01/174/002 20010403; UK EU/1/01/174/003 20010403; UK EU/1/01/174/004 20010403; UK EU/1/01/174/005 20010403; UK EU/1/01/174/006 20010403; UK EU/1/01/174/007 20010403; UK EU/1/01/174/008 20010403; UK EU/1/01/174/009 20010403; UK EU/1/01/174/010 20010403; UK EU/1/01/174/011 20010403; UK EU/1/01/174/012 20010403; UK EU/1/01/174/013 20010403; UK EU/1/01/174/014 20010403; UK EU/1/01/174/015 20010403; UK EU/1/01/174/016 20010403; UK EU/1/01/174/017 20010403; UK EU/1/01/174/018 20010403; UK EU/1/01/174/019 20010403; UK EU/1/01/174/020 20010403; UK EU/1/01/174/021 20010403
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Fish and Richardson
Citi
Chubb
Covington
UBS
Deloitte
Harvard Business School
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.